Update on US Regulatory Review of Roxadustat in Anemia of Chronic Kidney Disease

18 December 2020 -- The US Food and Drug Administration (FDA) has requested further clarifying analyses of clinical data, to complete its review of the New Drug Application (NDA) for roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials